Moderna-Merck Melanoma Breakthrough Shows 49% Mortality Reduction
Researchers at Moderna and Merck have made significant progress in developing a personalized mRNA treatment for melanoma, one of the most common and deadly forms of cancer in the US. According to Dr. Gian Vinelli, head of dermatology at Rochester Regional Health, the new vaccine has shown promising results in late-stage clinical trials.
The treatment works by combining the mRNA vaccine with the immunotherapy drug Keytruda to target specific mutations in the patient's tumor. Doctors collect samples of the tumor and blood, which are then analyzed to create a personalized vaccine tailored to each patient's unique markers.
When administered via injection, the body recognizes the tumor's specific markers and trains the immune system to attack cancer cells. In the clinical trial, patients experienced a 49% reduction in the risk of dying over the next five years.